Sun Xianze, deputy director of CFDA: the system of listing permission holders makes creative scientists rich first

Source: sun Xianze, deputy director of CFDA, CPPCC news, October 15, 2015: I personally believe that the scientific development of artemisinin has brought revolutionary changes to malaria control No matter which country or enterprise benefits from it later, it is the discovery of artemisinin that makes the scientists who have been struggling to explore the fight against malaria see the light, which makes the malaria that has been ravaging human beings for a long time to be cured and millions of lives to be saved Therefore, it is highly recognized by the international community and the great contribution of Professor Tu's research team to mankind In addition, it also enlightens us that the reform of new drug review and approval system in our country must be boldly promoted, and we must vigorously promote the development of new drugs While congratulating Professor Tu on winning the Nobel Prize, we are also deeply thinking about the reform of drug review and approval and how to better serve the creation of new drugs On August 13th this year, the State Council issued the opinions on the reform of the review and approval system for pharmaceutical and medical devices, marking the comprehensive start of the reform of the review and approval system The opinions defined 5 major objectives, 12 tasks and 4 Among the safeguard measures, to encourage the creation of new drugs is one of the overall requirements and important objectives of the reform In order to encourage the creation of new drugs, we need to innovate in the system, give priority to the review, simplify the procedures, and communicate in the technology, so as to truly form a review and approval system that is conducive to stimulating the innovation vitality In this reform, we have reclassified drugs, and are now reporting to the National People's Congress for authorization At the same time, we have introduced the system of listing license holders for the first time, which is also waiting for the authorization of the National People's Congress The system of marketing license holder, which is to separate the management of drug marketing license and production license, allows scientific research institutions and scientific and technological workers to apply for registration of new drugs This system is conducive to mobilizing the enthusiasm of researchers in the research and development of new drugs It can closely link the personal interests of researchers and the collective interests of research and development institutions with the research results and market benefits, so as to maximize the stimulation Develop the innovation power of scientific researchers We should let creative scientists and intellectuals get rich first The above excerpt is from the resume of sun Xianze in the CPPCC daily, born in June 1957 in Ganyu, Jiangsu Province, and graduated from Nanjing Pharmaceutical College (now China Pharmaceutical University) He was once a pharmaceutical engineer, workshop director and assistant to the director of Chengdu No.1 pharmaceutical factory, and then the director and deputy director of Sichuan drug administration; in June 2003, he was transferred to work in the State Food and drug administration On December 9, 2009, sun Xianze replaced Bian Zhenjia, who had been promoted to deputy director of the State Food and drug administration, and transferred to the Department of drug safety supervision as director In June 2011, sun Xianze took over the post of retired Xiao Yan, director of the Information Center (at the level of bureau) and Secretary of the Party committee of the State Food and drug administration In August 2012, he served as the deputy director and member of the Party group of the State Food and drug administration In March 2013, the State Food and drug administration was changed into the State Food and drug administration, and sun Xianze served as a member of the Party group of the State Food and drug administration In June 2014, he served as a member of the Party group and director of drug safety of the State Food and drug administration Since July 2015, sun Xianze has served as the deputy director, member of the Party group and director of drug safety of the State Food and drug administration Under the leadership of the General Administration, sun Xianze is in charge of the emergency management department, the science and technology and Standards Department, the China food and drug inspection and Research Institute (medical device standard management center), the drug review center, the organ service center, the Information Center (China food and drug regulatory data Center), and the China Pharmaceutical Association.